The azimilide post-infarct survival evaluation (ALIVE) trial

The American Journal of Cardiology
A J CammC M Pratt

Abstract

The AzimiLide post-Infarct surVival Evaluation (ALIVE) trial is a new clinical trial using an innovative design to examine the potential of azimilide, a novel type of antiarrhythmic, for improving survival in post myocardial infarction (MI) patients at high risk of sudden cardiac death. Azimilide is the first of a unique class of antiarrhythmic drugs that blocks both slow and rapid components of the delayed rectifier potassium currents in human myocardium. Preclinical studies have shown the drug to be effective in reducing cardiac tachyarrhythmias, even under ischemic conditions. Currently, azimilide is in Phase III trials for the treatment of supraventricular arrhythmias. The ALIVE study design is based on lessons learned from the Cardiac Arrhythmia Suppression Trials (CAST), the Survival With Oral d-Sotalol (SWORD) trial, and the European Myocardial Infarction Amiodarone Trial (EMIAT) and identifies recent post-MI patients at high risk of sudden cardiac death. The hypothesis underlying this trial is that azimilide will improve survival in this patient population. The ALIVE trial is designed as a double-blind, placebo-controlled, multinational trial that will overcome the shortcomings of previous antiarrhythmic trials by using...Continue Reading

References

Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial II Investigators

❮ Previous
Next ❯

Citations

Sep 14, 2014·Heart Failure Clinics·Lisa J Rose-JonesAnil K Gehi
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·A J Camm, Y G Yap
Nov 1, 2002·Current Treatment Options in Cardiovascular Medicine·B. John HynesGerald V. Naccarelli
Aug 10, 2002·Current Cardiology Reports·Gerald V NaccarelliJerry Luck
Feb 14, 2002·Clinical Cardiology·Deborah WolbretteAlan Kadish
May 24, 2000·Progress in Pediatric Cardiology·A Dubin
Nov 24, 1999·The American Journal of Cardiology·A Zivin, G H Bardy
May 24, 2000·The American Journal of Cardiology·J A Reiffel
Mar 10, 2004·Journal of Cardiovascular Electrophysiology·Gerald V NaccarelliJerry C Luck
Mar 5, 2004·Pharmacotherapy·J Jason Sims, Michael R Ujhelyi
Apr 16, 2004·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Bernhard KuchHeinz D Bolte
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Abrol, R L Page
Jul 2, 2005·Expert Opinion on Emerging Drugs·Ole Dyg PedersenChristian Torp-Pedersen
Dec 10, 1999·Journal of the American College of Cardiology·H V HuikuriR J Myerburg
Aug 17, 2010·Journal of Pharmacological Sciences·Yasuhide Watanabe, Junko Kimura
Sep 23, 2006·Journal of Pharmacological Sciences·Yasuhide WatanabeJunko Kimura
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N SinghJonnalagedda S M Sarma
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Fuhua ChenThomas S Klitzner
May 15, 2003·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N Singh
Jun 6, 2015·Circulation Research·Omair YousufRonald D Berger
Mar 24, 2000·Drugs·D Clemett, A Markham
Feb 10, 2000·Current Opinion in Cardiology·P T Sager
Feb 5, 1999·Current Opinion in Cardiology·D Wolbrette, H Patel
Feb 5, 1999·Current Opinion in Cardiology·P T Sager
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani
Aug 15, 2000·Journal of Cardiovascular Pharmacology·V Nand, S A Doggrell
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·T J Colatsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.